Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)
Launched by IRCCS SAN RAFFAELE · Mar 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The GYN-ART clinical trial is studying how different advanced radiotherapy techniques, like Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), and Stereotactic Body Radiotherapy (SBRT), affect women with gynecological cancers. Researchers want to learn more about the side effects these treatments may cause and how they impact the patients' recovery and well-being.
To participate in this study, women must be at least 18 years old and have been diagnosed with gynecologic cancer, receiving one of the advanced radiotherapy treatments mentioned. The trial is currently looking for participants, and those who join can expect regular follow-ups to monitor their health and any treatment-related effects. It's an opportunity to contribute to important research that could improve future care for women facing similar challenges.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • gynecologic cancer patients
- • \>18 years old
- • treated with advanced radiotherapy techniques (IGRT, IMRT, SBRT)
- Exclusion Criteria:
- • other tumors
- • \> 90 years old
About Irccs San Raffaele
IRCCS San Raffaele is a prestigious research hospital and clinical trial sponsor based in Milan, Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As an Institute for Research and Healthcare, it specializes in a wide range of therapeutic areas, including oncology, neurology, and cardiology, and is dedicated to translating scientific discoveries into effective clinical practices. With a multidisciplinary team of experts and state-of-the-art facilities, IRCCS San Raffaele plays a pivotal role in conducting rigorous clinical trials that contribute to the development of novel treatments and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, Mi, Italy
Patients applied
Trial Officials
andrei Fodor, MD
Principal Investigator
IRCCS San Raffaele Scientific Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported